We describe an AI-enabled, integrated Coronavirus drug discovery knowledgebase, free for the research community. Its goal is to make accessible up to date information relevant to drug discovery for SARS-CoV-2 and other coronaviruses. It builds on great knowledge from across therapeutic areas and provides unbiased, systematic, objective information to empower the international effort.
Cancer Research UK (C35696/A23187)
Wellcome Trust (WT212969/Z/18/Z)
Wellcome Trust (WT204735/Z/16/Z)
InstitutionTHE INSTITUTE OF CANCER RESEARCH
ORCID For Submitting Author0000-0003-3367-2519
Declaration of Conflict of InterestCM, AAA, EVF, PdM, ILM, JET, KHC, JC, DS, IC, PW and BAL are employees of the Institute of Cancer Research (ICR) which has a commercial interest in a range of drug targets. The ICR operates a Rewards to Inventors scheme through which employees of the ICR may receive financial benefit following commercial licensing. PW is a former employee of AstraZeneca and received research funding from Vernalis, Astex, AstraZeneca, BACIT and Sixth Element Capital/CRT Pioneer Fund. PW is a consultant/scientific advisory board member for NextechInvest, Storm Therapeutics, Astex Pharmaceuticals and CV6, and holds stock in Chroma Therapeutics, NextInvest and Storm Therapeutics. He is also a Non-Executive Director of Storm Therapeutics and the Royal Marsden NHS Trust and a Board Director of the nonprofit
Chemical Probes Portal. BAL is currently or has been a consultant to Astex Pharmaceuticals, GSK, Astelas Pharma and Difiniens AG (member of Astra Zeneca group). BAL
is a former employee of Inpharmatica Ltd. IC is currently or has been a consultant to Epidarex LLP, AdoRx Therapeutics and Enterprise Therapeutics, has received research funding from Astex, Merck KGaA, Janssen Biopharma, Monte Rosa Therapeutics and Sixth Element Capital/CRT Pioneer Fund, and holds stock in Monte Rosa Therapeutics AG. IC is a former employee of Merck Sharp & Dohme.